- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
6 result(s) found for: MSH.
Displaying page 1 of 1.
EudraCT Number: 2021-002855-12 | Sponsor Protocol Number: RM-493-034 | Start Date*: 2022-04-22 |
Sponsor Name:Rhythm Pharmaceuticals Inc. | ||
Full Title: A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Rece... | ||
Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) NL (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002446-39 | Sponsor Protocol Number: CUV025 | Start Date*: 2008-10-16 | ||||||||||||||||
Sponsor Name:Clinuvel Pharmaceuticals Limited | ||||||||||||||||||
Full Title: A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 Administered as A Subcutaneous Bioresorbable 16mg Implant in Patients Undergoin... | ||||||||||||||||||
Medical condition: Barrett's Oesohagus Cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002392-28 | Sponsor Protocol Number: RM-493-Supplementation-Therapy | Start Date*: 2014-11-28 |
Sponsor Name:Charité Univeritaetsmedizin Berlin | ||
Full Title: Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity | ||
Medical condition: Body weight is regulated within the hypothalamus. In rare cases mutations in genes, which are embedded in the signaling cascades of the hypothalamus lead to early onset severe obesity. POMC is one ... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000636-13 | Sponsor Protocol Number: CUV017 | Start Date*: 2008-06-17 | |||||||||||
Sponsor Name:Clinuvel Pharmaceuticals Limited | |||||||||||||
Full Title: A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) | |||||||||||||
Medical condition: Erythropoietic Protoporphyria (EPP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) IT (Completed) FR (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007015-89 | Sponsor Protocol Number: CUV011 | Start Date*: 2008-11-07 | |||||||||||||||||||||
Sponsor Name:Clinuvel Pharmaceuticals Limited | |||||||||||||||||||||||
Full Title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of CUV1647 for the Prophylactic Treatment of Pr... | |||||||||||||||||||||||
Medical condition: Pre-cancerous skin lesions | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) BE (Completed) FR (Ongoing) DE (Completed) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002873-24 | Sponsor Protocol Number: RM-493-035 | Start Date*: 2022-05-16 |
Sponsor Name:Rhythm Pharmaceuticals Inc. | ||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melano... | ||
Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
